Tabituximab barzuxetan (exclude Y90)
Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma.
For research use only. We do not sell to patients.
- CAS No.: 1612758-88-9
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
|
RDC Antibody |
Tabituximab barzuxetan (exclude Y90) is a immunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101), and exhibits antitumor activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1612758-88-9
-
SMILES
[Tabituximab barzuxetan (exclude Y90)]
-
Synonyms
OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz